Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort

European Journal of Cancer

Volumn 48, Issue 1, 2012, Pages 94-100

  Si, Lu ^a   Kong, Yan ^a   Xu, Xiaowei ^b   Flaherty, Keith T ^c   Sheng, Xinan ^a   Cui, Chuanliang ^a   Chi, Zhihong ^a   Li, Siming ^a   Mao, Lili ^a   Guo, Jun ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

BRAF; Melanoma; Mutation; NRAS; Overall survival

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; GENOMIC DNA;

ADULT; ARTICLE; COHORT ANALYSIS; EXON; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; ONCOGENE N RAS; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SUN EXPOSURE; ULCER;

ADULT; AGED; AMINO ACID SUBSTITUTION; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, RAS; GLUTAMIC ACID; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION RATE; MUTATION, MISSENSE; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; VALINE;

EID: 83255191650     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.06.056     Document Type: Article

References (40)

1. L.A. Fecher, S.D. Cummings, M.J. Keefe, and R.M. Alani Toward a molecular classification of melanoma J Clin Oncol 25 2007 1606 1620
2. J.L. Bos, E.R. Fearon, and S.R. Hamilton Prevalence of ras gene mutations in human colorectal cancers Nature 327 1987 293 297
3. L.J. van ′t Veer, B.M. Burgering, and R. Versteeg N-ras mutations in human cutaneous melanoma from sun-exposed body sites Mol Cell Biol 9 1989 3114 3116
4. A.P. Albino, D.M. Nanus, and I.R. Mentle Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype Oncogene 4 1989 1363 1374
5. N.J. Ball, J.J. Yohn, and J.G. Morelli Ras mutations in human melanoma: a marker of malignant progression J Invest Dermatol 102 1994 285 290
6. A. van Elsas, S.F. Zerp, and S. van der Flier Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma Am J Pathol 149 1996 883 893
7. S. Jiveskog, B. Ragnarsson-Olding, A. Platz, and U. Ringborg N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin J Invest Dermatol 111 1998 757 761
8. K. Omholt, S. Karsberg, and A. Platz Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression Clin Cancer Res 8 2002 3468 3474
9. M.S. Brose, P. Volpe, and M. Feldman BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 2002 6997 7000
10. A. Gorden, I. Osman, and W. Gai Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues Cancer Res 63 2003 3955 3957
11. R. Kumar, S. Angelini, and K. Czene BRAF mutations in metastatic melanoma: a possible association with clinical outcome Clin Cancer Res 9 2003 3362 3368
12. M. Shinozaki, A. Fujimoto, D.L. Morton, and D.S. Hoon Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas Clin Cancer Res 10 2004 1753 1757
13. R. Houben, J.C. Becker, and A. Kappel Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis J Carcinog 3 2004 6
14. D.Z. Chang, K.S. Panageas, and I. Osman Clinical significance of BRAF mutations in metastatic melanoma J Transl Med 2 2004 46
15. L.A. Akslen, S. Angelini, and O. Straume BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival J Invest Dermatol 125 2005 312 317
16. M. Kirschner, B. Helmke, and H. Starz Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases Melanoma Res 15 2005 427 434
17. J.A. Curtin, J. Fridlyand, and T. Kageshita Distinct sets of genetic alterations in melanoma N Engl J Med 353 2005 2135 2147
18. E. Edlundh-Rose, S. Egyházi, and K. Omholt NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing Melanoma Res 16 2006 471 478
19. W. Liu, J.W. Kelly, and M. Trivett Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma J Invest Dermatol 127 2007 900 905
20. E. Hacker, N.K. Hayward, T. Dumenil, M.R. James, and D.C. Whiteman The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population J Invest Dermatol 130 2010 241 248
21. J.A. Ellerhorst, V.R. Greene, and S. Ekmekcioglu Clinical correlates of NRAS and BRAF mutations in primary human melanoma Clin Cancer Res 17 2011 229 235
22. G.V. Long, A.M. Menzies, and A.M. Nagrial Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma J Clin Oncol 29 2011 1239 1246
23. K. Byrd-Miles, E.L. Toombs, and G.L. Peck Skin cancer in individuals of African, Asian, Latin-American, and American-Indian descent: differences in incidence, clinical presentation, and survival compared to Caucasians J Drugs Dermatol 6 2007 10 16
24. T.K. Eigentler, P.G. Buettner, U. Leiter, and C. Garbe Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry J Clin Oncol 22 2004 4376 4383
25. Hardwicke J, Brunt AM, Rylands G, Rayatt S. Ten-year Audit of melanoma in a Central England population. Acta Derm Venereol 2011; (in press).
26. K. Ishihara, T. Saida, and F. Otsuka Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update Int J Clin Oncol 13 2008 33 41
27. Z. Chi, S. Li, and X. Sheng Clinical presentation, histology, prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases BMC Cancer 11 2011 85
28. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 2006 4340 4346
29. Y. Kong, L. Si, and Y. Zhu Large scale analysis of KIT aberrations in Chinese patients with melanoma Clin Cancer Res 17 2011 1684 1691
30. K.T. Flaherty, I. Puzanov, and K.B. Kim Inhibition of mutated, activated BRAF in metastatic melanoma N Engl J Med 363 2010 809 819
31. R. Kefford, H. Arkenau, and M.P. Brown Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors J Clin Oncol 28 2010 [abstr 8503]
32. G.V. Long, R.F. Kefford, and P.J.A. Carr Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets) Ann Oncol 21 2010 LBA27 [abstr]
33. J. Bauer, P. Büttner, and R. Murali BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site Pigment Cell Melanoma Res 24 2011 345 351
34. N.E. Thomas, M. Berwick, and M. Cordeiro-Stone Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation? J Invest Dermatol 126 2006 1693 1696
35. W.M. Lin, A.C. Baker, and R. Beroukhim Modeling genomic diversity and tumor dependency in malignant melanoma Cancer Res 68 2008 664 673
36. B. Jovanovic, S. Egyhazi, and M. Eskandarpour Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations J Invest Dermatol 130 2010 618 620
37. R.Q. Qi, L. He, and S. Zheng BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han J Invest Dermatol 131 2011 1129 1138
38. T. Eisen, T. Ahmad, and K.T. Flaherty Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis Br J Cancer 95 2006 581 586
39. A. Demunter, M. Stas, H. Degreef, C. De Wolf-Peeters, and J.J. van den Oord Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma J Invest Dermatol 117 2001 1483 1489
40. J.N. Poynter, J.T. Elder, and D.R. Fullen BRAF and NRAS mutations in melanoma and melanocytic nevi Melanoma Res 16 2006 267 273